Cargando…

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study

There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort study to compare composite complete remission (CCR)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mustafa Ali, Moaath K., Corley, Elizabeth M., Alharthy, Hanan, Kline, Kathryn A. F., Law, Jennie Y., Lee, Seung Tae, Niyongere, Sandrine, Duong, Vu H., Emadi, Ashkan, Baer, Maria R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008336/ https://www.ncbi.nlm.nih.gov/pubmed/35433414 http://dx.doi.org/10.3389/fonc.2022.858202

Ejemplares similares

Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
por: Corley, Elizabeth M., et al.
Publicado: (2022)

Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
por: Corley, Elizabeth M., et al.
Publicado: (2022)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
por: Niyongere, Sandrine, et al.
Publicado: (2020)

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia
por: Lee, Aaron M., et al.
Publicado: (2022)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: a retrospective propensity score matching study
por: Wang, Miao, et al.
Publicado: (2023)

Therapy-related B-lymphoblastic leukemia after multiple myeloma
por: Kallen, Michael E., et al.
Publicado: (2022)

Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
por: Wang, Hongxia, et al.
Publicado: (2020)

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies
por: Feld, Jonathan, et al.
Publicado: (2021)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
por: Zhang, Keyuan, et al.
Publicado: (2023)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US
por: Vachhani, Pankit, et al.
Publicado: (2022)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies
por: Ucciero, Andrealuna, et al.
Publicado: (2023)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
por: Wu, Di, et al.
Publicado: (2021)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE
por: Wang, Yuexi, et al.
Publicado: (2023)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report
por: Shatilova, Aleksina, et al.
Publicado: (2021)

Perspectives of caregivers of older adults with acute myeloid leukemia during initial hypomethylating agents and venetoclax chemotherapy
por: Tan, Kelly R., et al.
Publicado: (2023)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
por: Martini, Gianluca, et al.
Publicado: (2023)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis
por: Ye, Fanghua, et al.
Publicado: (2023)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
por: Lim, Byungho, et al.
Publicado: (2022)

Clearance of bone marrow mast cells after hypomethylating agent and venetoclax for systemic mastocytosis associated with myeloid neoplasia
por: Pourhassan, Hoda, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

PB1872: SELINEXOR IN COMBINATION WITH VENETOCLAX AND HYPOMETHYLATING AGENTS FOR ACUTE MYELOID LEUKEMIA PATIENTS WITH SEVERE CO-MORBIDITIES
por: Chen, Fangli, et al.
Publicado: (2023)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

Real-World Experience of Adults With Acute Myeloid Leukemia on Hypomethylating Agents With or Without Venetoclax at a Comprehensive Cancer Center
por: Freeman, Tracelyn, et al.
Publicado: (2023)

PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
por: Kayser, Sabine, et al.
Publicado: (2023)

Check(point) or checkmate for acute myeloid leukemia?
por: Niyongere, Sandrine, et al.
Publicado: (2021)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
por: Tenold, Matthew E., et al.
Publicado: (2021)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ppaj6bj9oeeue5n9kbdgbkufan